PYPD News and Press, PolyPid Ltd. From 09/29/22

Why The Stock Market Is Down Today But wait, the stock market crash is over. At least, that is what some retail traders thought after yesterday’s broad-sector bounce led by tech. Waking up to the stock market today painted a much different picture. Even with this as the case, in ...

PolyPid ( NASDAQ: PYPD ) on Wednesday said it had got confirmation from Europe's drug regulator that its D-PLEX 100 product candidate for the treatment of surgical site infections was eligible to be submitted for a marketing authorization. The company said the product cand...

Centralized Procedure Allows for Submission of a Single Marketing Application to the European Medicines Agency that, if Approved, Would Allow D-PLEX 100 to be Marketed in All EU Member States D-PLEX 100 is Eligible for Centralized Procedure Under the Ther...

Intends to discuss the Clinical Outcomes and Next Steps for D-PLEX 100 for the Prevention of SSIs in Abdominal Surgery with the FDA and the EU Regulatory Authorities in Q1 2023 PETACH TIKVA, Israel, Sept. 19, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (&...

Efficacy Data of D-PLEX 100 in the Prevention of Post-Abdominal Surgery Incisional Infection will be Presented During a Podium Presentation PETACH TIKVA, Israel, Sept. 12, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “...

PolyPid Ltd. ( NASDAQ: PYPD ) dropped ~75% in value in the pre-market trading Friday after the Israeli company announced that its lead candidate D-PLEX100 did not meet the main goal in a Phase 3 trial for the prevention of surgical site infections ((SSIs)) in abdominal sur...

SHIELD I Study did not Achieve its Primary Endpoint of Reduction in Surgical Site Infections and Mortality In an FDA Requested Pre-specified Subgroup Analysis in Subjects with Incision Lengths over 20 centimeters (n=423), D-PLEX 100 + SoC Achieved a Statistically Signific...

Efficacy Data of D-PLEX 100 in reduction of Surgical Site Infection in Surgical Trauma Injuries will be Presented During a Podium Presentation PETACH TIKVA, Israel, Aug. 30, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the ...

PolyPid Ltd. (PYPD) Q2 2022 Results Conference Call August 10, 2022 08:30 AM ET Company Participants Bob Yedid - IR, LifeSci Advisors Dikla Czaczkes Akselbrad - CEO Ori Warshavsky - COO, U.S. Operations Conference Call Participants Gary Nachman - BMO ...

PolyPid press release ( NASDAQ: PYPD ): Q2 GAAP EPS of -$1.23 misses by $0.60 . As of June 30, 2022, the Company had cash and cash equivalents and deposits in the amount of $23.8 million, not including the second tranche of $2.5 million from the Kreos Capital...